Overview of Pharmacokinetic (PK) Study of Anti-Obesity Therapeutics

Obesity is genetically, metabolically, neurologically, endocrinologically, and environmentally regulated and increases the risk of metabolic disorders such as type II diabetes, hypertension, cancer, and cardiovascular disease. Several drug candidates and anti-obesity therapeutic approaches have been developed to address the molecular mechanisms and pathological characteristics of obesity. PK studies are often required to assess the efficacy of these potential drugs. Protheragen offers a PK study service for anti-obesity therapies based on our well-established and innovative drug discovery platform. Through our comprehensive solutions, we help to advance the field of personalized obesity treatment.

One-stop PK Research Programme to Accelerate Research on Anti-Obesity Therapies

Our highly trained scientists specialize in all aspects of anti-obesity drug development, preclinical research, etc., and have extensive hands-on experience.

Anti-Obesity Therapy Development

Anti-Obesity Gene Therapy Development

We offer a customized target-specific anti-obesity gene therapy development service. Our team delivers and regulates the expression of obesity-related genes to cells or animal models, and deeply probes changes in glucose metabolism, energy balance, obesity reversal, etc. We have a variety of precise gene editing techniques to ensure accurate regulation of obesity-related genes.

Anti-Obesity Cell Therapy Development

Relying on cutting-edge gene editing technology, we provide a full range of anti-obesity cell therapy development services. Cell types include stem cells, CAR-T cells, and others. By monitoring changes in histologic features, lipid metabolism, gene expression changes, etc., we comprehensively evaluate the effectiveness and safety of cell therapies.

Anti-Obesity Antibody Therapy Development

Antibody therapy is highly specific and is an innovative strategy for anti-obesity therapy. After we screen highly effective antibodies using phage display and hybridoma technology, we further optimize and produce them. These antibodies are then subjected to rigorous preclinical validation.

Anti-Obesity Tissue Engineering Therapy Development

We focus on targets related to adipose tissue function and energy metabolism for therapeutic design and preclinical studies. Through mechanisms such as drug delivery, promotion of fat metabolism, and tissue repair, anti-obesity tissue therapies sustain weight loss effects.

Anti-Obesity Nanotherapy Development

Anti-obesity nanotherapies have the advantages of low side effects, high tolerability, and excellent efficacy. We develop nanotechnology-based weight loss programs for white adipose tissue, brown adipose tissue, and so on.

Evaluation of Anti-Obesity Therapies

We combine in vivo and in vitro experiments and a variety of advanced analytical techniques to help advance the process from anti-obesity drug discovery to preclinical studies.

• Obesity Models: Obesity models play an important role in studying the physiological and genetic basis of obesity, exploring anti-obesity drug candidates, evaluating drug dosages, etc. We construct a variety of Cell and Animal Models (Mice, Rats, Rabbits, Beagles, etc.) and analyze the PK of the drugs, the mode of administration, and the effects.
• PK study: We develop one-stop PK study protocols to help accelerate research on anti-obesity therapies. Our first-class experimental skills and analytical capabilities ensure the delivery of high-quality results.
  • Drug absorption: Drug absorption is the process of transporting a drug from the site of administration to the circulatory system, which affects the concentration and speed at which it reaches the desired location. We study the absorption characteristics of anti-obesity drug candidates through in vitro and in vivo experiments.
  • Bioavailability: It is the proportion of the initially administered drug that enters the systemic circulation and provides a direct response to drug absorption. We use several techniques to assess the bioavailability of anti-obesity drugs.
  • Drug distribution: We assess the diffusion of the drug in the body and analyze the metabolism, excretion, and drug half-life of the anti-obesity drug in the body by measuring the concentration of the drug in the sample.
  • Drug metabolism: After biotransformation, drugs form a variety of metabolites through metabolism and excretion. The analysis and identification of these metabolites is a key part of understanding the efficacy and safety of anti-obesity drugs. We use high-performance liquid chromatography (HPLC), capillary electrophoresis (CE), thin layer chromatography (TLC), mass spectrometry (MS), and other techniques to analyze the structure, relative abundance, and metabolic pathways of metabolites.
  • Drug excretion: Excretion refers to the process of eliminating drugs from the body through different routes after absorption and metabolism. We use radioanalytical techniques to analyze the process of elimination of anti-obesity drugs from the body.

We also offer the following two study services in detail:

DMPK Study of Anti-Obesity Drugs

We have a wealth of animal models and advanced techniques for DMPK studies of anti-obesity drugs and tailor the analytical process to the client's actual research needs.

ADME Study of Anti-Obesity Drugs

ADME is determined by the structure of the drug. We have developed a variety of new research methods to support the ADME evaluation of anti-obesity drugs.

Workflow

We provide reliable service support for every stage of development of anti-obesity therapies and PK studies.

Applications

• Anti-obesity drug development: PK studies play a vital role in the development of anti-obesity drugs. They help researchers assess the safety and efficacy of potential drugs and select the most promising candidates for further development and research.
• Optimization of anti-obesity therapies: PK studies help in the optimization of anti-obesity therapies, i.e., optimizing the drug dosage based on various factors affecting the pharmacokinetics of the drug to ensure effective delivery to the target site.
• Drug-drug interactions: Pharmacokinetic studies help to identify potential drug-drug interactions, which is particularly important for the development of anti-obesity therapies using multiple drugs simultaneously.

Advantages

• Our experienced researchers respond quickly to the diverse needs of our clients' anti-obesity studies and provide professional communication and research support.
• We understand the specificity of each research project and design our anti-obesity therapy PK study protocols carefully, with real-time updates on project progress.
• We put the needs of our clients first and provide detailed reports on our anti-obesity PK analyses and attentive after-sales service.

What Other Quality Services Can We Offer?

We are committed to building personalized solutions to meet the various needs of our clients in obesity research. In addition to the development of anti-obesity therapies and preclinical studies, we have expanded our services to include comprehensive obesity risk assessment, precision diagnostic testing, and prospective obesity prediction. In obesity research, in-depth profiling of the microbiome composition, pathological characteristics, and obesity-related biomarkers is crucial. With rich testing experience, our team is also responsible for completing relevant experiments and responding flexibly to the testing needs of multiple types of samples. In addition, we offer personalized obesity management and weight control programs.

Publication Data

Frequently Asked Questions

What factors are associated with the absorption of anti-obesity drugs?

Absorption is the process by which a drug enters the blood circulation from the site of administration. The amount and speed of drug absorption are related to physical and chemical properties, the route of administration, and the absorption environment.

What are the factors affecting the distribution of anti-obesity drugs in the body?

• Plasma protein binding rate: The binding rate of drug and plasma protein is one of the important factors determining the distribution of drugs in the body.
• Tissue blood flow: There are differences in the distribution of blood flow in various tissues and organs. After absorption, the drug may rapidly reach a high concentration in organs with high blood flow and then may be redistributed to tissues with low blood flow.
• Cellular and capillary membrane permeability: The mechanism of drug permeation through cells is consistent with the mechanism of transmembrane transport. Undissociated and fat-soluble drugs are more likely to pass.
• Other factors: In addition to this, binding to tissue cellular components, the physicochemical properties of the drug, etc., also affect the distribution of the drug in the body.

Protheragen has long been committed to PK study research on anti-obesity drugs and tailors individual solutions to meet different research needs. Based on our state-of-the-art research platforms and reliable analyses, we provide strong support for the development of obesity treatments. Please feel free to contact us to discuss the detailed experimental process if you are interested in this area or have a need for it.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Bioanalysis of Anti-Obesity Therapeutics
• Obesity Models
• Pharmacodynamic Study of Anti-Obesity Therapeutics
• Safety Assessment of Anti-Obesity Therapeutics